Clinical service
Molecular Tumour Board Review
Multidisciplinary review of a case with molecular findings at the centre of the discussion.
Who it is for
- Clinicians with a case that would benefit from multidisciplinary molecular input.
- Hospitals without an established molecular tumour board.
What is reviewed
- Submitted clinical, pathological and molecular documentation
- Evidence supporting each potentially actionable finding
- Areas of genuine uncertainty in the case
What is delivered
- A structured decision summary
- Evidence tiers and actionability categories for each finding
- An explicit statement of what remains uncertain
- Suggested next questions
How this works alongside your care
- Analysis and interpretation are provided to you and, where you wish, directly to your treating team — who continue to prescribe, administer and direct your treatment.
- The work sits alongside your treating oncologist and is designed to strengthen that relationship rather than sit outside it.
- It is built for considered review. Anything acute or time-critical belongs with your treating team or your local emergency service, who can act immediately.
- It sets out what the evidence supports and where it remains uncertain. It does not forecast how a particular cancer will respond.
- The tumour board record is an expert opinion that supports the referring clinician’s decision-making and remains theirs to act on.
How to begin
Getting started
Nothing is charged for an enquiry, and scope is agreed in writing before any work starts.
Enquiries begin with a short message describing the situation and the question. From there, the documentation needed is agreed, and a scope and timeline are confirmed before any work starts.
The document checklist sets out what is typically needed. Missing items are worth identifying at the outset rather than mid-review.
Other services
Precision Oncology Consultation
A structured discussion of the molecular and clinical picture in a cancer case, and of the questions it raises.
Molecular Report Review
A detailed reading of a next-generation sequencing or molecular profiling report, including what the assay could and could not detect.
Cancer Second Opinion
An independent re-reading of the clinical, pathological and molecular record in a complex case.